Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
RALLYBIO Aktie jetzt für 0€ handeln | |||||
16.05. | Rallybio Corp - 8-K, Current Report | 1 | SEC Filings | ||
09.05. | Rallybio Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
08.05. | Rallybio GAAP EPS of -$0.21 beats by $0.05 | 1 | Seeking Alpha | ||
08.05. | RallyBio cuts deeper, culling 40% of workforce after halting work on lead drug | 1 | FierceBiotech | ||
08.05. | Rallybio Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
08.05. | Rallybio Corp - 8-K, Current Report | 2 | SEC Filings | ||
23.04. | Citizens JMP maintains Rallybio stock at Market Perform | 1 | Investing.com | ||
11.04. | Evercore ISI cuts Rallybio stock rating on study concerns | 1 | Investing.com | ||
09.04. | RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks | 2 | Zacks | ||
08.04. | Citizens JMP cuts Rallybio stock rating following program halt | 1 | Investing.com | ||
08.04. | Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints | 1 | Benzinga.com | ||
08.04. | Rallybio discontinues lead drug for rare maternal disorder | 1 | BioPharma Dive | ||
08.04. | Rallybio shares tumble 36% after RLYB212 program halt | 1 | Investing.com | ||
08.04. | Rallybio-Aktien stürzen nach Einstellung des RLYB212-Programms um 36% ab | - | Investing.com Deutsch | ||
08.04. | Rallybio abandons lead program after phase 2 data in rare maternal disorder disappoint | 1 | FierceBiotech | ||
08.04. | Rallybio Decides To Discontinue RLYB212 Development | 2 | RTTNews | ||
08.04. | Rallybio Corp - 8-K, Current Report | 1 | SEC Filings | ||
08.04. | Rallybio ends RLYB212 program after trial setback | 1 | Investing.com | ||
08.04. | Rallybio beendet RLYB212-Programm nach Rückschlag in klinischer Studie | 1 | Investing.com Deutsch | ||
13.03. | Rallybio Corp - 10-K, Annual Report | 3 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 92,75 | +0,60 % | BioNTech-Milliarden-Deal Vorlage für BioNxt Solutions? Bayer-Aktie mit Kaufempfehlung! | Der Milliarden-Deal von BioNTech und Bristol-Myers Squibb war ein echter Paukenschlag und hat die Biotech-Branche wieder wach geküsst. Während Analysten ihr Kursziel für den deutschen Biotech-Überflieger... ► Artikel lesen | |
CUREVAC | 4,738 | -1,82 % | mRNA-Monsterdeal!: BioNTech schluckt CureVac - Aktie explodiert um über 30 Prozent! | © Foto: picture alliance/dpa | Sebastian GollnowBioNTech übernimmt CureVac für 1,25 Milliarden US-Dollar - aus Rivalen wird ein Team im Kampf gegen Krebs. Der Impfstoff-Pionier will mit dem Deal auch... ► Artikel lesen | |
AMGEN | 256,95 | +0,53 % | EHA 2025: Regeneron's Lynozyfic with Amgen's Kyprolis combo emerges for R/R MM | ||
NOVAVAX | 6,040 | +0,60 % | Novavax: CIC And Flu Vaccine Candidates Induce Immune Responses Similar To Licensed Comparators | WASHINGTON (dpa-AFX) - Novavax, Inc. (NVAX) reported results of the initial cohort of COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza Phase... ► Artikel lesen | |
BIOGEN | 112,75 | -0,35 % | UCB & Biogen: Phase 3 Trial Of Dapirolizumab Pegol In Systemic Lupus Erythematosus Meets Main Goal | WESTON (dpa-AFX) - UCB (UCB) and Biogen Inc. (BIIB) presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,080 | 0,00 % | PALATIN TECHNOLOGIES INC - 8-K, Current Report | ||
BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
VIVOSIM LABS | 1,580 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
OCUGEN | 1,039 | +5,72 % | Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST-Modifier Gene Therapy Candidate for Stargardt Disease | MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von Bauchspeicheldrüsenkrebs... ► Artikel lesen | |
VIKING THERAPEUTICS | 22,655 | +0,35 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25
Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 7,608 | +5,78 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy ... | With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median... ► Artikel lesen | |
BIO-GATE | 1,000 | +3,09 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,500 | -0,79 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen |